TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23864403

Group type: EXPERIMENTAL
Intervention: Culturally-informed intervention (Grady Nia Project)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Treatment as usual (Control)
Number of subjects: 89
Study: 21171837

Group type: EXPERIMENTAL
Intervention: OPAC programme (outreach, problem solving, adherence, continuity)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 133
Study: 19365151

Group type: EXPERIMENTAL
Intervention: ABIO-08/01 (10 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: ABIO-08/01 (20 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: ABIO-08/01 (40 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 17606461

Group type: EXPERIMENTAL
Intervention: Atraumatic 22G needle
Number of subjects: 27

Group type: COMPARATOR
Intervention: Traumatic needle (TN)
Number of subjects: 27
Study: 15086488

Group type: EXPERIMENTAL
Intervention: High producer genotypes for IL-6 (G/G and G/C) and TNF-alpha (G/A and A/A)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: High and intermediate producer genotypes for IL-10 (G/G and G/A)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: TNF-alpha high producer genotype (G/A and A/A)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: IL-6 high producer genotypes
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: TNF-alpha high producer genotype
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: IL-10 high/intermediate producer genotype
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Cytokine genotype combinations (TNF-alpha high producer and IL-6 high producer; IL-6 high producer and IL-10 low producer)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: TNF-alpha high producer and IL-10 low producer genotype combination
Number of subjects: 183
Study: 11747684

Group type: EXPERIMENTAL
Intervention: Alendronate (5 mg/day or 10 mg/day)
Number of subjects: 670

Group type: EXPERIMENTAL
Intervention: Raloxifene (60 or 120 mg/day)
Number of subjects: 670

Group type: EXPERIMENTAL
Intervention: Combination hormone replacement therapy (HRT)
Number of subjects: 670

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 670

Group type: EXPERIMENTAL
Intervention: Alendronate, Raloxifene, or Combination HRT
Number of subjects: 670
Study: 9676945

Group type: EXPERIMENTAL
Intervention: Tc-99m HMPAO labeled leukocyte scintigraphy
Number of subjects: 23

Group type: COMPARATOR
Intervention: Tc-99m nanocolloid scintigraphy
Number of subjects: 23
Study: 7826249

Group type: EXPERIMENTAL
Intervention: Carbamazepine (400 mg single dose) before amiodarone therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carbamazepine (400 mg single dose) after one month of amiodarone therapy (400 mg daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amiodarone (400 mg daily for one month)
Number of subjects: 0
Study: 3292345

Group type: EXPERIMENTAL
Intervention: Simethicone
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study: 29574365

Group type: EXPERIMENTAL
Intervention: Fulvestrant 500 mg (days 0, 14, 28, then every 28 days)
Number of subjects: 462

Group type: COMPARATOR
Intervention: Anastrozole 1 mg (daily)
Number of subjects: 462
Study: 28242871

Group type: EXPERIMENTAL
Intervention: PF-04958242
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 26307942

Group type: EXPERIMENTAL
Intervention: Computer-assisted behavioral treatment for CUD with tobacco intervention and nicotine-replacement therapy (NRT)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Historical control group (treatment for CUD but not tobacco)
Number of subjects: 32
Study: 23142295

Group type: EXPERIMENTAL
Intervention: Osteochondral autologous transplantation (OAT)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Microfracture (MF)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Debridement (D)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Intact articular cartilage (IAC)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: All groups (OAT, MF, D, IAC)
Number of subjects: 102
Study: 22017924

Group type: EXPERIMENTAL
Intervention: VoorZorg (Nurse Family Partnership adapted for the Netherlands)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 0
Study: 19157297

Group type: EXPERIMENTAL
Intervention: Artesunate (ATS)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Quinine (QN)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 16862038

Group type: EXPERIMENTAL
Intervention: Consumer-directed personal care services (PCS)
Number of subjects: 2008

Group type: COMPARATOR
Intervention: Traditional Medicaid PCS
Number of subjects: 2008

Group type: EXPERIMENTAL
Intervention: Consumer-directed PCS
Number of subjects: 2008

Group type: COMPARATOR
Intervention: New PCS applicants
Number of subjects: 2008
Study: 14616157

Group type: EXPERIMENTAL
Intervention: Lamivudine monotherapy
Number of subjects: 36
Study: 10695692

Group type: EXPERIMENTAL
Intervention: Alendronate sodium, 5 mg/d (increased to 10 mg/d after 2 years)
Number of subjects: 6459

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6459
Study: 9586534

Group type: EXPERIMENTAL
Intervention: Chewing gum (sugar-free), chewed for 20 minutes five times each day after toothbrushing and Peridex rinse
Number of subjects: 150

Group type: COMPARATOR
Intervention: No chewing gum (control group)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Chewing gum (sugar-free)
Number of subjects: 150
Study: 8267492

Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Nicotinic acid
Number of subjects: 61
Study: 2685479

Group type: EXPERIMENTAL
Intervention: Home care intervention
Number of subjects: 13

Group type: COMPARATOR
Intervention: Randomized controlled trials (as a subgroup of home care)
Number of subjects: 13
Study: 786310

Group type: EXPERIMENTAL
Intervention: Piracetam therapy at a dosage of 3 X 1600 mg per day
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Piracetam therapy at a dosage of 3 X 800 mg per day
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 31145350

Group type: EXPERIMENTAL
Intervention: Forced-air warming system set at 42°C (group F2)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Forced-air warming system set at 38°C (group F1)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Regular blanket (group C)
Number of subjects: 243
Study: 29034009

Group type: EXPERIMENTAL
Intervention: Decitabine as epigenetic priming induction (Arm A)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard induction (Arm B)
Number of subjects: 24
Study: 25220709

Group type: EXPERIMENTAL
Intervention: LNG/EE contraceptive patch
Number of subjects: 2160

Group type: COMPARATOR
Intervention: Combination oral contraceptive 20 (LNG 100 μg per EE 20 μg)
Number of subjects: 2160

Group type: COMPARATOR
Intervention: Combination oral contraceptive 30 (LNG 150 μg per EE 30 μg)
Number of subjects: 2160
Study: 23769143

Group type: EXPERIMENTAL
Intervention: Menthol candy drops
Number of subjects: 99

Group type: COMPARATOR
Intervention: PEG‐E
Number of subjects: 99
Study: 20934757

Group type: EXPERIMENTAL
Intervention: 8 g/day oral essential amino acids (EAAs)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: EAA supplementation
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: WIG (without-infection group)
Number of subjects: 80
Study: 17901913

Group type: EXPERIMENTAL
Intervention: Early computed tomography (CT) within one hour of admission
Number of subjects: 99
Study: 16460374

Group type: EXPERIMENTAL
Intervention: Progressive, structured, 3-month physical exercise program
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100
Study: 15504997

Group type: EXPERIMENTAL
Intervention: 10 microg exenatide twice daily
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: 5 microg exenatide twice daily
Number of subjects: 377

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 377
Study: 11787912

Group type: EXPERIMENTAL
Intervention: Carrying own medical records
Number of subjects: 21
Study: 8950733

Group type: EXPERIMENTAL
Intervention: Amniotic fluid insulin concentration (AFI) based treatment
Number of subjects: 123

Group type: COMPARATOR
Intervention: Mean maternal blood glucose values (MBG) based treatment
Number of subjects: 123
Study: 1904845

Group type: EXPERIMENTAL
Intervention: Screening Van (SV) with full economic incentive
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Aphakic Motivator (AM) with full economic incentive
Number of subjects: 90

Group type: COMPARATOR
Intervention: Basic Eye Health Worker (BW)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Mass Media (MM)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Partial economic incentive interventions
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 90
Study: 7138234

Group type: EXPERIMENTAL
Intervention: Clonidine hydrochloride and naltrexone hydrochloride combination treatment
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Clonidine hydrochloride
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Naltrexone hydrochloride
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Withdrawal symptoms (anxiety, restlessness, muscular aching)
Number of subjects: 11
Study: 31584030

Group type: EXPERIMENTAL
Intervention: Fluoride varnish containing CPP-ACP
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fluoride varnish containing xylitol
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fluoride varnish with 0.9% difluorosilane
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fluoride varnish with prior oral prophylaxis
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fluoride varnish without prior oral prophylaxis
Number of subjects: 60
Study: 28656910

Group type: EXPERIMENTAL
Intervention: levocetirizine 10 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: levocetirizine 5 mg + montelukast 10 mg
Number of subjects: 120
Study: 25872649

Group type: EXPERIMENTAL
Intervention: Oral Methotrexate (MTX)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 23879226

Group type: EXPERIMENTAL
Intervention: Hospital Elder Life Program (HELP)
Number of subjects: 0
Study: 21460396

Group type: EXPERIMENTAL
Intervention: Verum penetrating acupuncture
Number of subjects: 10

Group type: COMPARATOR
Intervention: Non-penetrating sham needles
Number of subjects: 10
Study: 19588534

Group type: EXPERIMENTAL
Intervention: 595 nm pulsed dye laser (PDL) treatment, 4 treatments at 2-week intervals, 15 J/cm2 energy, 3 ms pulse length, no cooling, 7 mm spot size with 10% overlap
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 595 nm pulsed dye laser (PDL) treatment
Number of subjects: 20
Study: 17521782

Group type: EXPERIMENTAL
Intervention: Trivalent A/C/W135 polysaccharide vaccine
Number of subjects: 360

Group type: COMPARATOR
Intervention: Tetravalent A/C/Y/W135 polysaccharide vaccine
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 360
Study: 15334027

Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 87
Study: 11114571

Group type: EXPERIMENTAL
Intervention: High-flux hemodiafiltration with cellulose dialyzers
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: High-flux hemodiafiltration with synthetic dialyzers
Number of subjects: 11
Study: 9586609

Group type: EXPERIMENTAL
Intervention: Holmium laser resection of the prostate (HoLRP)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Neodymium:yttrium-aluminum-garnet visual laser ablation of the prostate (VLAP)
Number of subjects: 44
Study: 8083794

Group type: EXPERIMENTAL
Intervention: Pre-brushing rinse (PBR)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Plain tap water
Number of subjects: 4

Group type: COMPARATOR
Intervention: Brushed only
Number of subjects: 4

Group type: COMPARATOR
Intervention: Sterile water
Number of subjects: 4
Study: 2636654

Group type: EXPERIMENTAL
Intervention: Ketoacid mixture (KAM) containing 10.9% (R,S) alpha-keto-beta-methylvalerate, meal dose of 6.2 +/- 0.25 g or 9.3 +/- 0.55 g
Number of subjects: 0
Study: 606773

Group type: EXPERIMENTAL
Intervention: A/Shope vaccine (200 CCA units/dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: A/X-53 vaccine (200 CCA units/dose)
Number of subjects: 0
Study: 31162829

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 142

Group type: COMPARATOR
Intervention: Cyclophosphamide
Number of subjects: 142
Study: 29202204

Group type: EXPERIMENTAL
Intervention: Yoga intervention (8-week program)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 151
Study: 26442395

Group type: EXPERIMENTAL
Intervention: Nerve Stimulator‐Guided Group (NSG)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Ultrasound guided group (USG)
Number of subjects: 36
Study: 23370663

Group type: EXPERIMENTAL
Intervention: 100 mcg/kg A(1-7)
Number of subjects: 34

Group type: COMPARATOR
Intervention: 300 mcg/kg A(1-7)
Number of subjects: 34
Study: 20621509

Group type: EXPERIMENTAL
Intervention: rt-PA
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study: 19437312

Group type: EXPERIMENTAL
Intervention: 30 mg/kg single dose of azithromycin
Number of subjects: 99

Group type: COMPARATOR
Intervention: 20 mg/kg single dose of azithromycin
Number of subjects: 99
Study: 17294232

Group type: EXPERIMENTAL
Intervention: Ramelteon 16 mg
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 15548447

Group type: EXPERIMENTAL
Intervention: Oxybutynin
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Tolterodine
Number of subjects: 128
Study: 11380220

Group type: EXPERIMENTAL
Intervention: Oral paste containing antibiotics polymyxin E, tobramycin, and amphotericin B (PTA group)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study: 9239626

Group type: EXPERIMENTAL
Intervention: Standing biofeedback training device (experimental group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 60
Study: 8505745

Group type: EXPERIMENTAL
Intervention: Pranayama (yogic breathing and stretch)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Relaxation
Number of subjects: 71

Group type: COMPARATOR
Intervention: Visualization
Number of subjects: 71
Study: 3086019

Group type: EXPERIMENTAL
Intervention: Helium washout technique (wVD/VT)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Conventional Bohr's method (VD/VT)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Rebreathing technique (AVD/VT)
Number of subjects: 55
Study: 29504780

Group type: EXPERIMENTAL
Intervention: Reduced nicotine content (RNC) cigarettes (0.4 mg/g to 15.8 mg/g nicotine)
Number of subjects: 839

Group type: EXPERIMENTAL
Intervention: Reduced nicotine content (RNC) cigarettes (0.4 mg/g)
Number of subjects: 839

Group type: EXPERIMENTAL
Intervention: Reduced nicotine content (RNC) conditions
Number of subjects: 839

Group type: COMPARATOR
Intervention: Normal nicotine content (NNC) cigarettes
Number of subjects: 839
Study: 27475338

Group type: EXPERIMENTAL
Intervention: Intravenous vitamin B6 (60 mg of intravenous pyridoxal 5'-phosphate after each thrice-weekly hemodialysis session)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 56
Study: 24356792

Group type: EXPERIMENTAL
Intervention: Colesevelam 3.75 g/day
Number of subjects: 357

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 357
Study: 21707472

Group type: EXPERIMENTAL
Intervention: Cognitive remediation therapy (CRT)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Usual treatment
Number of subjects: 59
Study: 19276646

Group type: EXPERIMENTAL
Intervention: RTS,S/AS02
Number of subjects: 306

Group type: COMPARATOR
Intervention: Rabies vaccine
Number of subjects: 306
Study: 17591468

Group type: EXPERIMENTAL
Intervention: 4.9-mm-diameter one-plane bending high resolution videoendoscope
Number of subjects: 122

Group type: COMPARATOR
Intervention: 5.9-mm-diameter standard videoendoscope
Number of subjects: 122
Study: 15370183

Group type: EXPERIMENTAL
Intervention: Individualized homeopathy treatment
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Active treatment (continued)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Active treatment (switched to placebo)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Overall subjects
Number of subjects: 48
Study: 11591835

Group type: EXPERIMENTAL
Intervention: Clomethiazole (68 mg/kg IV over 24 hours)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Clomethiazole in TACS subgroup
Number of subjects: 190

Group type: COMPARATOR
Intervention: Placebo in TACS subgroup
Number of subjects: 190
Study: 9869786

Group type: EXPERIMENTAL
Intervention: 0.2% brimonidine tartrate
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 18
Study: 8087784

Group type: EXPERIMENTAL
Intervention: Tamoxifen therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endocrine therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard doses of chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Future clinical trials
Number of subjects: 0
Study: 3195529

Group type: EXPERIMENTAL
Intervention: Antibiotics plus 5 mL/kg/d for four days of IgM-enriched immunoglobulin intravenously
Number of subjects: 60

Group type: COMPARATOR
Intervention: Antibiotics alone
Number of subjects: 60
Study: 6897618

Group type: EXPERIMENTAL
Intervention: Bromhexin tablets 8 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Bisolvon tablets 8 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Bromhexin, DAK and Bisolvon
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Bromhexine (overall pharmacokinetics)
Number of subjects: 10
Study: 30924785

Group type: EXPERIMENTAL
Intervention: Telemonitoring strategy
Number of subjects: 84
Study: 29160099

Group type: EXPERIMENTAL
Intervention: rAAV1-CMV-hGAA gene therapy
Number of subjects: 0
Study: 26934400

Group type: EXPERIMENTAL
Intervention: Cycle ergometer-based exercise program
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard physical rehabilitation protocol
Number of subjects: 24
Study: 24874911

Group type: EXPERIMENTAL
Intervention: Individualized substrate modification (ISM)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Stepwise ablation (SA)
Number of subjects: 124
Study: 23433618

Group type: EXPERIMENTAL
Intervention: Group 1 (postcards with enrollment information)
Number of subjects: 5807

Group type: EXPERIMENTAL
Intervention: Group 2 (postcards with enrollment and fluoride varnish information)
Number of subjects: 5807

Group type: COMPARATOR
Intervention: Group 3 (no postcards)
Number of subjects: 5807
Study: 20648041

Group type: EXPERIMENTAL
Intervention: Plant sterol margarine
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: No-trans-fat margarine
Number of subjects: 53

Group type: COMPARATOR
Intervention: Butter
Number of subjects: 53
Study: 17561982

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT) in Turner syndrome
Number of subjects: 16

Group type: COMPARATOR
Intervention: Oral contraceptives in controls
Number of subjects: 16
Study: 16036040

Group type: EXPERIMENTAL
Intervention: Inhibition of the renin‐angiotensin‐aldosterone axis and the sympathetic nervous system
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Investigation of endothelin, matrix metalloproteinases, and cytokines
Number of subjects: 0
Study: 12499033

Group type: EXPERIMENTAL
Intervention: 20 microg ethinyl estradiol and 75 microg gestodene (GSD)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 20 microg ethinyl estradiol and 150 microg desogestrel (DSG)
Number of subjects: 36
Study: 9822044

Group type: EXPERIMENTAL
Intervention: Long-term treatment protocol (LTP) with PGE1: 2-hour infusions (60 microg PGE1, 5 days each week for 4 weeks), followed by twice a week for 4 weeks, then monitoring for 3 months.
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Short-term treatment protocol (STP) with PGE1: 2-hour infusion over 2 days (1st day: morning 20 microg, afternoon 40 microg; 2nd day: morning and afternoon 60 microg), followed by full dosage for subsequent cycles.
Number of subjects: 109
Study: 8024636

Group type: EXPERIMENTAL
Intervention: Ranitidine (300 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Famotidine (40 mg)
Number of subjects: 12
Study: 2644595

Group type: EXPERIMENTAL
Intervention: Clotrimazole 500 mg vaginal suppositories, administered once weekly for 2 weeks
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Clotrimazole 500 mg vaginal tablets, administered once a month during prophylactic phase
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo, administered once a month during prophylactic phase
Number of subjects: 42
Study: 886526

Group type: EXPERIMENTAL
Intervention: Radiotherapy with a spread of 60 ± 12 hr
Number of subjects: 121

Group type: COMPARATOR
Intervention: Radiotherapy with a spread of 156 ± 12 hr
Number of subjects: 121
Study: 30016185

Group type: EXPERIMENTAL
Intervention: LVHL2 (low-velocity, high-load, twice-weekly)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: LVHL1 (low-velocity, high-load, once-weekly)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: HVLL2 (high-velocity, low-load, twice-weekly)
Number of subjects: 54

Group type: COMPARATOR
Intervention: CON (no-exercise control)
Number of subjects: 54
Study: 28151904

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided pulsed radiofrequency (PRF) stimulation on the interfascial area of the TM
Number of subjects: 36

Group type: COMPARATOR
Intervention: Ultrasound-guided interfascial block (IFB) with 10 mL of 0.6% lidocaine
Number of subjects: 36
Study: 25995169

Group type: EXPERIMENTAL
Intervention: Icotinib administered with food
Number of subjects: 22

Group type: COMPARATOR
Intervention: Icotinib administered without food
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Icotinib pharmacokinetics model
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: CYP2C19 genotype influence
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Age and albumin concentration influence
Number of subjects: 22